The blood protein tester SomaLogic Inc. has teamed up with the British biotechnology company Ixaka Ltd. teamed up in a research project to investigate the development of aptamer-based bispecific therapeutics a company press release.
SomaLogic’s SOMAmer reagents are being investigated as potential candidates for combination with Ixaka’s anti-cancer aptamers called anti-CD3 molecules.
The ability of SOMAmer reagents to bind to any target protein with high specificity and affinity makes them ideal for the development of novel therapies for oncology, ”said Nebojsa Janji, SomaLogic’s chief science officer, in the press release. “We hope to be able to expand this collaboration with Ixaka in the future to support new treatments for other therapeutic areas.”
© 2021 BizWest Media LLC